Products
Deflazacort is commercially available in tablet form (Calcort). It has been approved in many countries since 1986.
Structure and properties
Deflazacort (C25H31NO6, Mr = 441.5 g/mol) differs from prednisolone in having an oxazoline ring at C16-C17.
Effects
Deflazacort (ATC H02AB13) has anti-inflammatory, antiallergic, and immunosuppressive properties. The mineralocorticoid effect of deflazacort is very low.
Indications
- Primary or secondary adrenal insufficiency.
- Congenital NNR hyperplasia
- Rheumatoid arthritis, psoriatic arthritis
- Acute rheumatic fever
- Systemic lupus erythematosus
- Polyarteritis nodosa
- Arteritis cranialis
- Wegener’s granulomatosis
- Non-purulent thyroiditis
- Severe acute dermatoses
- Bronchial asthma
- Sarcoidosis with pulmonary infiltration
- Exogenous allergic alveolitis
- Desquamative interstitial pneumonia
- Chorioiditis
- Chorioidoretinitis
- Iritis
- Iridocyclitis
- Idiopathic thrombocytopenia
- Acquired autoimmune hemolytic anemia
- Palliative treatment of acute leukemia in children.
- Leukemias and lymphomas in adults
- Nephrotic syndrome
- Ulcerative colitis
- Crohn’s disease
- Chronic aggressive hepatitis
Dosage
According to the professional information. Tablets are usually taken in the morning during or after breakfast. Therapy should be started gradually and discontinued gradually.
